The intensive care unit (ICU) is a specialized ward of a hospital that provides special medical attention to patients who require critical medical care.  The main types of ICU beds on the market are electric beds, semi-electric beds, and manual beds. Electric ICU beds are controlled by a handset or control panel, rather than by medical personnel manually repositioning the bed. The various applications include pediatric intensive care unit, neonatal intensive care unit, psychiatric intensive care unit, cardiac intensive care unit, neurological intensive care unit, trauma intensive care unit, post-operative recovery unit, surgical intensive care unit, and mobile intensive care unit that are used by general and acute care hospitals, specialized hospitals, multi-specialty hospitals, ambulatory surgery centers (ASC), and others. The ICU beds market research report is one of a series of new reports from The Business Research Company that provides ICU beds market statistics, including ICU beds industry global market size, regional shares, competitors with a ICU beds market share, detailed ICU beds market segments, market trends and opportunities, and any further data you may need to thrive in the ICU beds industry. This ICU beds market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global icu beds market will grow from $1.89 billion in 2022 to $2.01 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global icu beds market is expected to grow to $2.62 billion in 2027 at a CAGR of 6.9%. The market for ICU beds is experiencing exponential growth. Increasing COVID-19 cases across the globe pressurizing governments of emerging and developed countries to increase their intensive care capacities. Public health systems releasing funds to procure the needed hospital infrastructure, with ICU beds being one of the important requirements. The frequent outbreaks of pandemic diseases such as Influenza, Ebola, and the recent COVID-19, has put enormous pressure on healthcare authorities and health services to draft and discuss preparedness plans that includes the increase in number of ICU beds, to accommodate critically ill patients. During pandemics, most patients require ICU admission and this drives the market for ICU beds. Even in most well-developed countries, ICU beds are often close to capacity during such out-breaks. In United States, there are an estimated 34.2 ICU beds per 10,000 people, yet there is a surge in demand during recent COVID-19 pandemic. In Italy, there are about 12.5 ICU beds per 10,000 people. Due to the recent outbreak, with the rate of increase in the number of patients in intensive care with COVID-19, the demand for number of ICU beds continues to change. In China and India, it is only 3.6 and 2.3 beds per 10,000 people respectively, and the demand in such developing countries is huge. Patients with severe COVID-19 disease require approximately 14 days of respiratory support in ICU. Such lengthy treatment time will further stress resources. Therefore, the frequent outbreaks of pandemics are expected to drive the market for ICU beds. Critical care is often described as expensive care that includes high cost of resources. In United States, although ICU beds comprise less than 10% of hospital beds, ICU departments consume 22% of total hospital costs. ICU beds tend to cost threefold higher than a bed in a general ward. ICU beds cost between $25,000 and $30,000, significantly more than other medical/surgical beds, which typically cost $5,000 to $10,000 a bed. Bariatric beds are even more expensive, which are nearly about $35,000 to $40,000 each. The escalating demand for critical care services put financial strain on both health care systems, and also on patients who pay completely or partially out-of-pockets for these services. Therefore, high prices of ICU beds are challenging the growth of this market. The launch of smart beds is the key trend gaining popularity in the ICU beds market. Smart beds help to automate and digitalize patient monitoring, improving overall efficiency. The smart beds are designed to facilitate the patient’s movement and help them regain normal movement faster, with the presence of monitoring systems. For example, in August 2022, Dozee, an India based medical equipment manufacturer, partnered with Midmark India, an India based hospital bed manufacturers, and launched a connected bed platform for non-ICU settings. Dozee's sensor-based technology uses artificial intelligence (AI) to track vital parameters of the patient. Major players in the ICU beds market are Invacare Corporation, Paramount Bed Holdings Co. Ltd., Medline Industries Inc., Stiegelmeyer GmBH & Co. KG, Gendron Inc., LINET Group SE, Joerns Healthcare LLC., Span-America Medical Systems Inc., Malvestio S.P.A., and Merivaara Corp. North America was the largest region in the ICU beds market in 2022. Western Europe was the second largest region in the global ICU beds market. The regions covered in the global Intensive Care Unit (ICU) Beds market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the ICU beds market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The Intensive Care Unit (ICU) Beds market consists of sales of gatch beds, low air loss beds, motor powered beds, and collapsible hospital beds. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global ICU beds market is segmented - 1) By Type: Electric Beds, Semi-Electric Beds, Manual Beds 2) By Application: Pediatric Intensive Care Unit, Neonatal Intensive Care Unit, Psychiatric Intensive Care Unit, Cardiac Intensive Care Unit, Neurological Intensive Care Unit, Trauma Intensive Care Unit, Post-Operative Recovery Unit, Surgical Intensive Care Unit, Mobile Intensive Care Unit 3) By End Use: General And Acute Care Hospitals, Specialized Hospitals, Multi-Specialty Hospitals, Ambulatory Surgery Centres (ASC), Other End Uses

Cardiac rhythm management (CRM) devices and equipment are used to manage the heart rate or rhythm by generating electrical impulses or shocks in order to get the heart back to its normal functions. CRM devices are used to treat and manage arrhythmia-related diseases such as cardiac arrests, heart failure, or cardiac arrhythmias. The main products of cardiac rhythm management devices and equipment are pacemakers, defibrillators, and cardiac resynchronization therapy (CRT). A pacemaker is a small device that's placed in the chest to control the heartbeat. It's used to prevent the heart from beating too slowly. The defibrillators are implantable cardioverter defibrillators and external defibrillators. Cardiac resynchronization therapy (CRT) includes CRT-defibrillators (CRT-D), CRT-pacemakers (CRT-P). There are implantable pacemakers and external pacemakers. The applications involved are bradycardia, tachycardia, heart failure, and others that are used by various end-users such as hospitals, ambulatory surgical centres, and physician’s clinics. The cardiac rhythm management (CRM) devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiac rhythm management (CRM) devices and equipment market statistics, including cardiac rhythm management (CRM) devices and equipment industry global market size, regional shares, competitors with a cardiac rhythm management (CRM) devices and equipment market share, detailed cardiac rhythm management (CRM) devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac rhythm management (CRM) devices and equipment industry. This cardiac rhythm management (CRM) devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiac rhythm management (CRM) devices and equipment market size will grow from $15.13 billion in 2022 to $16.19 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiac rhythm management (CRM) devices and equipment market size is expected to grow to $20.05 billion in 2027 at a CAGR of 5.5%. The rising incidences of cardiovascular diseases such as cardiac arrhythmia, ischemic heart disease, and hypertension is driving the CRM devices market. Sedentary lifestyles and medical conditions such as high cholesterol, high blood pressure, obesity, and diabetes are major causes of cardiovascular diseases. According to the World Health Organization, cardiovascular diseases account for about 31% of all global deaths. Most of these deaths occur due to heart attacks and strokes. As more people suffer from cardiovascular diseases, the demand for cardiac rhythm management and devices is expected to increase. The risks associated with cardiac rhythm management devices and equipment market is acting as a restraint on the market. CRM devices may pose potential risks such as post-implant infections and contraindications in patients undergoing any type of radiation therapy or diagnosis. Implantable CRM devices contain complementary metal-oxide-semiconductor (CMOS) which may get damaged due to therapeutic doses of radiation. Also, as the implants are highly sensitive devices, any dysfunction may have life-threatening consequences for the patients. The considerable number of risks involved in using CRM devices are affecting the growth of the market. Technologies such as subcutaneous implantable cardioverter-defibrillator (S-ICD) and leadless cardiac pacemakers (LCP) are being developed to overcome complications with transvenous lead and other CRM devices. The novel modular cardiac rhythm management (mCRM) system allows for the coordination of leadless pacing and defibrillator therapy delivery by providing wireless intra-body communication between devices. This communication is possible by a combination of anti-tachycardia pacing-enabled LCP and S ICD. For instance, Medtronic developed the leadless pacemaker Micra which can be placed in the heart through veins and is self-contained within the heart. Manufacturers of cardiac rhythm management devices and equipment are governed by various regulatory bodies such as the FDA in the USA. The United States Food and Drug Administration recalls any product with safety issues or defects that can endanger the consumer. The FDA recalled the Platinium implantable cardiac defibrillator and resynchronization therapy defibrillator due to issues with hardware configuration and functioning. The company had to discard all non-implanted Platinium devices and follow up with all patients implanted with these devices. Major players in the cardiac rhythm management (CRM) devices and equipment market are Abbott, Medtronic, Biotronik, Cardiac Science Corporation, Schiller AG, Hill-Rom Holdings Inc., GE Healthcare, Integer, Biotelemetry, and Neovasc. North America was the largest region in the global cardiac rhythm management (CRM) devices and equipment market in 2022. Western Europe was the second-largest region in the cardiac rhythm management (CRM) devices and equipment market. The regions covered in the global cardiac rhythm management (CRM) devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiac rhythm management (CRM) devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The cardiac rhythm management (CRM) devices and equipment market consist of sales of Pacemakers, (implantable pacemakers, external pacemakers), defibrillators (implantable cardioverter defibrillators, external defibrillators), and cardiac resynchronization therapy (CRT-defibrillators, CRT-pacemakers) that are used for rhythm management. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiac rhythm management (CRM) devices and equipment market is segmented - 1) By Product: Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT) 2) By End User: Hospitals, Ambulatory surgical centers, Physicians Clinics 3) By Application: Bradycardia, Tachycardia, Heart Failure, Other Applications 4) By Pacemakers: Implantable Pacemakers, External Pacemakers 5) By Defibrillators: Implantable Cardioverter Defibrillators, External Defibrillator 6) By Cardiac Resynchronization Therapy (CRT): CRT-Defibrillators (CRT-D), CRT-Pacemakers (CRT-P)

Telehealth is engaged in providing telehealth services for the smooth functioning of healthcare services. Telehealth is the use of electronic data and telecommunications technology to promote long-distance medical healthcare services, patient and professional health education, public health, and health management. Technologies comprise streaming media, teleconferencing, the Web, store-and-forward imaging, and terrestrial and wireless communications. The main types of telehealth solutions include software, services, and hardware that are delivered on-premise and through the cloud. These are used by healthcare providers, patients, and payers across various healthcare applications, including teleradiology, teleconsultation, tele-ICU, telestroke, telepsychiatry, and teledermatology. The telehealth market research report is one of a series of new reports from The Business Research Company that provides telehealth market statistics, including telehealth industry global market size, regional shares, competitors with a telehealth market share, detailed telehealth market segments, market trends and opportunities, and any further data you may need to thrive in the telehealth industry. This telehealth market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global telehealth market size grew from $102.98 billion in 2022 to $132.63 billion in 2023 at a compound annual growth rate (CAGR) of 28.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The telehealth market size is expected to grow to $349.11 billion in 2027 at a CAGR of 27.4%. The outbreak of COVID-19 propelled the growth of the telehealth market. Telehealth is recognized to be an effective tool in the fight against the COVID-19 pandemic, to prevent the spread of the virus due to travelling to clinics and hospitals. Individuals, both patients and healthcare providers, are increasingly moving towards these online platforms. For instance, Teladoc Health, a virtual healthcare company based in the USA, has seen a huge increase in virtual visits, with an increase of 92% in total visits in the first quarter. Teladoc announced that the US subscription amounted to 43 million users in the first quarter of 2020, up 61% from 27 million users in the same quarter in 2019. Therefore, the outbreak of COVID-19 contributed to the growth of the telehealth market. The data security concern associated with the potential mishandling of patient data is expected to hamper the growth of the telehealth market in the coming years. The healthcare sector is digitizing business management and data management systems and is introducing new technologies to increase performance and minimize costs, but many weaknesses have been identified in this technology in several cases. The healthcare sector is regularly targeted by cyber-criminals who are searching for some tool in their armor to carry out their hacks, and several of these attacks have been successful. According to the Healthcare Protection Vision Study from CyberMDX released in February 2020, nearly 30% of healthcare delivery organizations (HDOs) have suffered a data breach in the last 12 months. Therefore, the security concerns regarding patient data restrain the growth of the telehealth market. Major companies operating in the telehealth sector are focusing on developing advanced solutions for telehealth that help remote monitoring easily. For instance, in April 2020, Royal Philips, a technology company that is engaged in healthcare, lighting, and consumer well-being markets, introduced Avalon CL Fetal and Maternal Pod and Patch for remote monitoring. The goal of the new wireless Avalon CL Fetal and Maternal Pod and Patch is to minimize unwanted physical contacts between physicians and patients, which is of quite significance during the COVID-19 pandemic. In July 2020, BioTelemetry, Inc., a US-based remote medical technology company focused on the delivery of health information to improve quality of life and reduce the cost of care, acquired On.Demand, a remote patient monitoring (RPM) and coaching platform that is operated by Envolve People Care, Inc. for an undisclosed amount. Through this acquisition, BioTelemetry becomes an exclusive provider to Centene Medicaid members for diabetes RPM services. Envolve PeopleCare, Inc., a US-based company focused on transformative health management through education and empowerment. Major players in the telehealth market are Teladoc Health Inc., American Well, MDLive, Doctor on Demand, GlobalMed, Siemens Healthineers, Cisco Systems, Inc., Medtronic, Dictum Health, Inc., Koninklijke Philips N.V., GE Healthcare, AMC Health, Medvivo Group Ltd., Iron Bow Technologies, Telespecialists LLC, MedWeb, IMediplus Inc., Vsee, Chiron Health, Zipnosis, Allscripts Healthcare Solutions, Honeywell International Inc., Right Health, Boston Scientific Corporation, Care Innovations LLC, InTouch Technologies, Inc., Encounter Telehealth, HelloMD, SnapMD, Inc., and OpenTeleHealth. North America was the largest region in the telehealth market in 2022. The regions covered in the telehealth market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the telehealth market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The telehealth market includes revenues earned by entities by live videoconferencing, asynchronous video (aka store-and-forward), remote patient monitoring (RPM) and mobile health (mhealth). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global telehealth market is segmented - 1) By Component: Software, Services, Hardware 2) By Mode Of Delivery: Cloud-based, On-Premise 3) By Application: Teleradiology, Tele-Consultation, Tele-ICU, Tele-Stroke, Tele-Psychiatry, Tele-Dermatology, Other Applications 4) By End-User: Healthcare Providers, Patients, Payers, Other End-Users

Telemedicine services are health care services provided via video chat, phone calls, and text messages. Patients can use telemedicine for physical examination as well as to ask questions regarding health concerns. The main types of telemedicine services are web-based, cloud-based, and on-premises. Cloud-based solutions provide healthcare providers financial, logistical, and functional advantages over in-house client-server systems. Cloud computing provides cost flexibility as well as the potential for cost reductions. The different technologies include store and foreward, real time and is used in teleradiology, telepsychiatry, telepathology, teledermatalogy, telecardiology. The telemedicine services market research report is one of a series of new reports from The Business Research Company that provides telemedicine services market statistics, including telemedicine services industry global market size, regional shares, competitors with a telemedicine services market share, detailed telemedicine services market segments, market trends and opportunities, and any further data you may need to thrive in the telemedicine services industry. This telemedicine services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global telemedicine services market size will grow from $103.06 billion in 2022 to $131.75 billion in 2023 at a compound annual growth rate (CAGR) of 27.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global telemedicine services market size is expected to grow to $262.33 billion in 2027 at a CAGR of 18.8%. Rising cases of COVID 19 infections across the globe is driving the telemedicine services market. As of December 2020, the total number of active cases around the world is around 19,649,961 million and expected to increase until the availability of vaccines. Telemedicine services will provide healthcare services to the COVID 19 affected people as they cannot step out to avail the services. Rising cases of COVID 19 infections across the globe is expected to boost the demand for the telemedicine services market. Breach in the data makes the patients uncomfortable on sharing personal information that would help the physicians to diagnose the patients' health, affecting the telemedicines market negatively. Telemedicine services are provided online or through calls and might not have much security for storing the data, or in some cases the telemedicine companies may use third-party servers to store the customer data to cut down the maintenance cost, which might lead to easy data breaches. For instance, according to Hippa Journal, the official publication of the American Health Information Management Association, the Office for Civil Rights (OCR) of the Department of Health and Human Services (HHS) received 347 reports of healthcare data breaches involving 500 or more records between January 1, 2022, and June 30, 2022. Telemedicine is increasingly being accepted and insurance companies and government-regulated health care programs are increasingly covering telemedicine services in their plans. The governments are probing companies to make changes to the policies to cover the services under their schemes. For instance, in March 2020, in response to the coronavirus outbreak, the US government announced that private insurers will be covering the cost of coronavirus testing and telemedicine services for patients. In April 2022, Patient Square Capital, a US-based healthcare investment firm, acquired SOC Telemed for an undisclosed amount. Through this acquisition, Patient Square Capital will help SOC Telemed to be well-positioned to fulfill the expanding demands of patients, clinicians, and our hospital partners. SOC Telemed is US-based company specializing in telemedicine technology and solutions. Major players in the telemedicine services market are AMD Global Telemedicine Inc., Philips Healthcare, Cisco Systems, Inc., McKesson Corporation, Allscripts Healthcare Solutions Inc., GE Healthcare Ltd., Cerner Corporation, BioTelemetry Inc. and Teladoc. North America was the largest region in the telemedicine services market in 2022. Asia-Pacific was the second largest region in global telemedicine services market. The regions covered in the global telemedicine services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the telemedicine services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The telemedicine services market includes revenues earned by entities by providing teleneuropsychology, telenursing, telepharmacy, and telerehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global telemedicine services market is segmented - 1) By Technology outlook: Store and Foreward, Real time 2) By Application: Teleradiology, Telepsychiatry, Telepathology, Teledermatalogy, Telecardiology 3) By Type: Web-based, Cloud-based, On-premises

Psychedelic drug refers to a group of psychoactive drugs that alter perception, mood, and thought processes. All of the senses are affected by psychedelics, which change a person's thinking, perception of time, and emotions. These include chemicals such as Lysergic acid diethylamid (LSD) and plants such as peyote. These medications are used to treat a variety of brain conditions. The main types of psychedelic drugs are lysergic acid diethylamid, ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. Lysergic Acid Diethylamide (LSD) is also known colloquially as acid. LSD is manufactured in crystalline form and then mixed with other inert ingredients or diluted as a liquid to produce an ingestible form. The various disease indications include depression and PTSD, which could be natural or synthetic. The numerous applications include treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The psychedelic drugs market research report is one of a series of new reports from The Business Research Company that provides psychedelic drug market statistics, including psychedelic drug industry global market size, regional shares, competitors with a psychedelic drug market share, detailed psychedelic drug market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global psychedelic drugs market size grew from $4.2 billion in 2022 to $4.83 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The psychedelic drugs market size is expected to grow to $8.31 billion in 2027 at a CAGR of 14.5%. The increase in the cases of mental illnesses is expected to propel the growth of the psychedelic drug market going forward. Mental illnesses refer to health conditions involving changes in emotion, thinking, or behavior. Mental illnesses include conditions such as distress and post-traumatic stress disorder. Psychedelic drugs are used to treat depression and post-traumatic stress disorder, and their regular usage decreases mental illnesses. For instance, in 2020, according to the National Alliance on Mental Illness (NAMI), a US-based mental health organization, 21% of adults in America were suffering from mental illness in 2020, which amounted to 52.9 million people. Therefore, an increase in the number of cases of mental illnesses is driving the growth of the psychedelic drug market. The introduction of "depression spray" is the key trend gaining popularity in the psychedelic drug market. Major companies operating in the psychedelic drug market are introducing nasal spray drugs for major depressive disorders to sustain their position in the market. For instance, in August 2021, Hikma Pharmaceuticals plc, a UK based pharmaceutical company, launched KLOXXADO. KLOXXADO is an 8 mg nasal spray containing naloxone HCl. This spray is used for the immediate care of patients, both adults and children, with known or suspected opioid overdoses, as shown by respiratory depression and/or central nervous system depression. In April 2022, Numinus, a Canada-based company that manufactures psychedelic medicine with holistic, integrated psychotherapy, acquired Novamind for a deal amount of $20.77 million. With this acquisition, Numinus is expected to expand its psychotherapy clinics in the US and develop advanced psychedelic programs. Novamind is a US-based mental health company and manufacturer of psychedelic medicine. Major players in the psychedelic drug market are Johnson & Johnson, Pfizer, Hikma Pharmaceuticals PLC, Roche Holding AG, Merck & Co Inc., Jazz Pharmaceuticals plc, COMPASS Pathways PLC, Celon Pharma S.A., Numinus Wellness Inc., AbbVie, Mylan N.V., Avadel, NeuroRx Inc., Klarisana, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Allergan Inc., Mota Ventures Corp., Seelos Therapeutics, Emmes Company, and Novatris International AG. North America was the largest region in the psychedelic drug market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the psychedelic drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The psychedelic drug market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global psychedelic drugs market is segmented - 1) By Type: Lysergic Acid Diethylamid (LSD), Ketamine, Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Salvia 2) By Disease Indication: Depression, PTSD 3) By Origin: Natural, Synthetic 4) By Application: Treatment-Resistant Depression, Opiate addiction, Post- Traumatic Stress Disorder, Narcolepsy, Panic Disorders 5) By Distribution Channel: Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy

Telepsychiatry refers to the delivery and assistance of clinical psychiatric care, including medical care, providing patient education, health information services, and self-care through telecommunications and digital communication technologies. The main types of telepsychiatry are routine telepsychiatry, forensic telepsychiatry, crisis telepsychiatry, and in-home telepsychiatry. Routine telepsychiatry involves a consistent provider or small group of providers serving a regular caseload of consumers in previously scheduled blocks of time. The age groups are adult, paediatric and adolescent, and geriatric. The various end-users involved are community mental health centers, specialty care settings, skilled nursing facilities, home care, and other end-users. The telepsychiatry market research report is one of a series of new reports from The Business Research Company that provides telepsychiatry market statistics, including telepsychiatry industry global market size, regional shares, competitors with a telepsychiatry market share, detailed telepsychiatry market segments, market trends and opportunities, and any further data you may need to thrive in the telepsychiatry industry. This telepsychiatry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global telepsychiatry market size grew from $7.7 billion in 2022 to $9.78 billion in 2023 at a compound annual growth rate (CAGR) of 27.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The telepsychiatry market size is expected to grow to $22.52 billion in 2027 at a CAGR of 23.2%. The increase in demand for mental health treatment is expected to propel the growth of the telepsychiatry market going forward. Mental health refers to the cognitive, behavioral, and emotional well-being of a person. Psychologists are reporting a large increase in demand for the treatment of anxiety and depression. For instance, in 2021, according to the American Psychological Association, a US-based professional organisation that represents psychologists, nearly 84% of psychologists who treat anxiety disorders said they have seen increased demand for anxiety treatment since the pandemic when compared with the last decade when it was 74%. Also, 72% of psychologists said that there was an increase in depression prevalence compared with 60% in 2020. Therefore, the increase in demand for mental health treatment is driving the growth of the telepsychiatry market. Technological advancements are key trends gaining popularity in the telepsychiatry market. Major companies operating in the telepsychiatry market are focused on developing new technological solutions to strengthen their position. For instance, in December 2021, Zoom Video Communications Inc., a US-based communications technology company, along with Cerner Corp.'s electronic health record platform and a US-based company that provides telepsychiatry, launched an integration option for facilitating easier access to telehealth within Cerner's EHR. This includes the in-chart notifications when the patient has entered the appointment waiting room and the ability to send an invite link to additional participants, like family members, interpreters, and other care providers, and is accessible to join the session. In December 2021, Quartet Health, a US-based tech-enabled mental health care company, acquired InnovaTel Telepsychiatry for an undisclosed amount. Through this acquisition, Quartet will develop market-leading care delivery capabilities to complement its existing ecosystem of high-performing clinicians who practise in-network on behalf of health insurance plans. InnovaTel Telepsychiatry is a US-based telepsychiatry service provider of psychiatrists, nurse practitioners, and licenced clinical social workers. Major players in the telepsychiatry market are AllScripts Healthcare Solutions Inc., Cerner Corporation, Sodexo S.A., LogistiCare Solutions LLC, The Allure Group, Aramark Corporation, Alere Inc., Flatworld Solution, Integrated Medical Transport, ABM Industries Inc., Advanced Telemed Services, American Telepsychiatrists, Encounter Telehealth LLC, InnovaTel Telepsychiatry, SOC Telemed, and Telemynd. North America was the largest region in the telepsychiatry market in 2022. The regions covered in the telepsychiatry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the telepsychiatry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The telepsychiatry market includes revenues earned by entities by providing psychiatric evaluation and diagnosis services, individual therapy services, group therapy services, and family therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global telepsychiatry market is segmented - 1) By Type: Routine Telepsychiatry, Forensic Telepsychiatry, Crisis Telepsychiatry, In-Home Telepsychiatry 2) By Age Group: Adult, Pediatric and Adolescent, Geriatric 3) By End-Use: Community Mental Health Centers, Specialty Care Settings, Skilled Nursing Facilities, Homecare, Other End-Users 

Branded generics refer to an unregistered drug that is marketed under a brand name and provides patients and healthcare providers with a benefit that encourages them to choose the brand. These are the generic medications that have a unique brand name on the market. They might be advertised similarly to how branded medications are. The main drug classes of branded generics are alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid-lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, and other drugs. The alkylating agents of branded generics refer to a subclass of antineoplastic or anticancer medications that work by preventing the conversion of DNA into RNA, which halts the creation of proteins. Alkylating chemicals change the hydrogen atoms on DNA to alkyl groups, which causes cross-links to form inside the DNA chain and has cytotoxic, mutagenic, and cancerous consequences. The various routes of administration of branded generics include topical, oral, parenteral, and other routes. They are in various medical conditions including oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, analgesics and anti-inflammatory, and other diseases. The branded generics market research report is one of a series of new reports from The Business Research Company that provides branded generics market statistics, including branded generics industry global market size, regional shares, competitors with a branded generics market share, detailed branded generics market segments, market trends and opportunities, and any further data you may need to thrive in the branded generics industry. This branded generic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global branded generics market size grew from $304.16 billion in 2022 to $329.98 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The branded generics market size is expected to grow to $464.58 billion in 2027 at a CAGR of 8.9%. The increasing prevalence of chronic diseases will drive the growth rate of branded generics market. Chronic diseases are long-lasting sicknesses that often cannot be healed, however, they are curable and controllable. Chronic diseases are increasing due to the increasing use of tobacco products, poor nutrition, physical inactivity, excessive use of alcohol, and others. Customers across the globe are more inclined toward branded generics to treat chronic diseases as they purchase them at a lower cost than usual medications. For instance, in September 2020, according to a research report published by American Action Forum, chronic disease prevalence and costs are rising in the United States. They are expected to keep rising as the disease prevalence among children and young adults rises. Chronic disease is a serious healthcare problem since the rising cost of chronic disease in the United States totals $3.7 trillion annually, which is around 19.6% of the country's gross domestic product. Thus an increase in the prevalence of chronic diseases is expected to boost the demand for branded generics during the forecast period. The strategic partnership is a key trend in the branded generics market. The companies operating in branded generics are entering into a partnership with relevant companies to leverage each other's resources and expand into new markets. In December 2021, Biocon Ltd., an India-based fully integrated biopharmaceutical company that develops affordable biosimilars, generic formulations & complex APIs, entered into a partnership with Tabuk Pharmaceuticals. The partnership will open the door for Biocon's entry into the MENA area, which will now include Jordan, Lebanon, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq. This will help create a robust worldwide portfolio of goods, either directly or through strategic alliances, to provide patients all over the world with access to inexpensive treatments. These medications' marketing authority will be held by Tabuk Pharmaceuticals, which is also in charge of their registration, importation, and promotion in Saudi Arabia and other Middle Eastern nations. Tabuk Pharmaceuticals is a Saudi Arabia-based company that manufactures and markets branded and generic pharmaceutical products. In July 2021, Lupin, an India-based pharmaceutical company offering branded and generic formulations, biosimilars, and active pharmaceutical ingredients (APIs), acquired Southern Cross Pharma Pvt Ltd (SCP) for an undisclosed amount. Through this acquisition, Generic Health, an Australia-based wholly-owned subsidiary of global pharma major Lupin Limited, will have access to more than 60 registered products with approximately USD 22 million in sales. It will result in the growth of value offer and market share of Lupin in the Australian market. Southern Cross Pharma Pvt Ltd (SCP) is an Australia-based pharmaceutical company engaged in developing, registering, and distributing generic products. Major players in the branded generics market are Pfizer Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, AstraZeneca, Apotex Inc., Zydus Cadila, Dr. Reddy's Laboratories Ltd., Viatris, Inc., and Valeant Pharmaceuticals International, Inc., North America was the largest region in the branded generics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the branded generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The branded generics market consists of sales of glucophage, lopressor, and trimox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global branded generics market is segmented - 1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering Drugs, Anti-depressants, Anti-psychotics, Anti-Epileptics, Other Drugs 2) By Route of Administration: Topical, Oral, Parenteral, Other Routes of Administration 3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-inflammatory, Other Applications

Physicians and other health practitioners are healthcare professionals that provide medical care. Physicians are medical doctors that are trained in healing. Other healthcare professionals include nurses, diagnostic device operators, and chemists. The main types of physicians and other practitioners are specialist doctors, primary care doctors, podiatrists, physical therapists, optometrists, and chiropractors. Optometrists are primary health care professionals who are skilled to evaluate the eyes for vision deficiencies, symptoms of injury, ocular diseases or abnormalities, and general health issues. The different expenditure types include public and private that are used by male and female. The physicians and other health practitioners market research report is one of a series of new reports from The Business Research Company that provides physicians and other health practitioners market statistics, including physicians and other health practitioners industry global market size, regional shares, competitors with a physicians and other health practitioners market share, detailed physicians and other health practitioners market segments, market trends and opportunities, and any further data you may need to thrive in the physicians and other health practitioners industry. This physicians and other health practitioners market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global physicians and other health practitioners market grew from $1,520.55 billion in 2022 to $1,628.68 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The physicians and other health practitioners market is expected to grow to $2,050.08 billion in 2027 at a CAGR of 5.9%. The physicians and other health practitioners market growth is aided by stable economic growth forecasted in many developed and developing countries. The International Monetary Fund (IMF) predicts that the global GDP growth will be 3.3% in 2020 and 3.4% in 2021. Recovering commodity prices, after a significant decline in the historic period is further expected to aid the market growth. Developed economies are also expected to register stable growth during the forecast period. Additionally, emerging markets are expected to continue to grow slightly faster than the developed markets in the forecast period. Stable economic growth is expected to increase investments in end user markets, thereby driving the market during forecast period. Inadequate public health insurance is one of the major barriers for the growth of the overall healthcare industry. Lack of public health insurance coverage makes it difficult for patients to obtain health services. According to a recent report released by WHO and the World Bank, 400 million people do not have access to essential health services, and 6% of people in low- and middle-income countries were tipped into or pushed further into extreme poverty because of health spending. Inadequate public health insurance schemes in certain developing economies will be a major barrier to proper health protection and will restrain the growth of the physicians and other health practitioners market during the forecast period. Physicians and other health practitioners are increasingly using e-prescriptions to reduce errors and improve service quality. Electronic prescribing or e-prescribing (e-Rx) is the computer-based electronic generation, transmission and filling of a medical prescription. E-prescribing allows a physician, pharmacist, nurse practitioner, or physician assistant to electronically transmit a new prescription or renewal authorization to a community or mail-order pharmacy. E-prescribing is beneficial to physicians as it reduces errors due to handwritten prescriptions. The E-prescribing trend provides scope for improving physicians and other health professionals’ service quality. Major companies in the physicians and other health practitioners market include IHH Healthcare, MEDNAX, Fresenius Medical Care AG & Co. KGaA, NHS England, US Physical Therapy, Henry Schein, Inc., Healthway Medical Corp Ltd., and universal health services. North America was the largest region in the physicians and other health practitioners market in 2022. Asia-Pacific was the second largest region in the physicians and other health practitioners market. The regions covered in the physicians and other health practitioners market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the physicians and other health practitioners market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The physicians and other health practitioners market includes revenues earned by entities by providing specialized care services by professionals such as neurologists, urologists, and cardiologists. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global physicians and other health practitioners market is segmented - 1) By Type: Specialist Doctors, Primary Care Doctors, Podiatrists, Physical Therapists, Optometrists, Chiropractors 2) By End User Gender: Male, Female 3) By Type of Expenditure: Public, Private Subsegments Covered: Doctors of Osteopathy, Psychiatrists, Psychologists, Other Healthcare Providers, Anesthesiologists, Cardiologists, Dermatologists, Obstetricians/ Gynecologists, Geriatricians, Neurologists, Neuropathologists, Pediatricians, Radiologists, Other Primary Care Doctors, General Podiatry, Podiatric Surgery, Podiatric Sports Medicine, Podopaediatrics